Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome
Abstract
CONTEXT: An altered lipid profile is common in polycystic ovary syndrome (PCOS) and is usually characterized by increased triglycerides and low high-density lipoprotein (HDL)-cholesterol levels. In the general population, these alterations are often associated with the increase of small low-density lipoproteins (LDLs) in the so-called "atherogenic lipoprotein phenotype" (ALP) that determines a further increase of cardiovascular risk. In this study, we evaluated the presence of ALP in the plasma of women with PCOS. SETTING: Measurements and analysis of LDL size were performed at the Clinic of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, Zurich. PCOS patients were recruited at the Department of Clinical Medicine, University of Palermo, and the Department of Obstetrics and Gynecology, University of Pisa. PATIENTS: Thirty patients with PCOS (hyperandrogenism and chronic anovulation) and 24 matched controls were studied. Anthropometric data, blood glucose, serum insulin lipid profile, and LDL size and subclasses were evaluated. RESULTS: Compared with controls, patients with PCOS had higher plasma concentrations of insulin and triglycerides and lower HDL-cholesterol concentrations but no differences in LDL-cholesterol and total cholesterol. Patients with PCOS had smaller LDL size due to a reduction in LDL subclass I, with a concomitant increase in LDL subclasses III and IV. Fourteen PCOS patients had an increase of smaller LDL particles, and it represented the second most common lipid alteration after decrease in HDL-cholesterol. However, because in this PCOS population hypertriglyceridemia was only present in two patients, complete ALP was relatively uncommon. CONCLUSIONS: Increase of type III or type IV LDL subclasses is a common finding in PCOS and represents the second most common lipid alteration after HDL-cholesterol decrease. However, in our PCOS patients, because of relatively low triglyceride levels, complete ALP is uncommon.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Slight variations such as alterations in lipoprotein particle dimensions and elevation in LDL II and IV subtypes could potentially contribute to increased susceptibility to macrovascular disease in people with PCOS.
“However, even slight variations, such as alterations in the dimensions of lipoprotein particles and an elevation in LDL II and IV subtypes, could potentially contribute to an increased susceptibility to macrovascular disease in people [107].”
A comprehensive lipid profile indicating high risk of atherosclerosis is usually not apparent in PCOS due to relatively low triglyceride levels.
“However, a comprehensive lipid profile that indicates a high risk of developing atherosclerosis is usually not apparent due to relatively low levels of triglycerides.”
In PCOS, fat metabolism is a key marker of long-term risk for cardiovascular problems, typically manifesting as reduced HDL cholesterol.
“A key marker of a person’s long-term risk for cardiovascular problems is how they metabolize fat if they have PCOS. Typically, this manifests as reduced levels of HDL cholesterol.”
The citation lists haven’t been fetched yet
References 31 · Cited by 121
- Authors
- Berneis, K., Rizzo, M., Lazzaroni, V., Fruzzetti, F., & Carmina, E.
- Affiliations
- University Hospital Zurich (CH)
- University of Palermo (IT)
- University of Pisa (IT)
- Corresponding author
- Carmina, Enrico
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-01-01
- Volume
- 92
- Issue
- 1
- Pages
- 186-189
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2137562767
- Cited by
- 121
- References
- 31
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 8 · 2014: 2 · 2013: 5 · 2012: 3
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- polycystic ovary syndrome, atherogenic lipoprotein phenotype, LDL particle size, HDL cholesterol, triglycerides, hypertriglyceridemia, hyperandrogenism, insulin, cardiovascular risk, dyslipidemia
- MeSH terms
- Adult, Female, Humans, Insulin, Cholesterol, HDL, Lipoproteins, LDL, Particle Size, Phenotype, Polycystic Ovary Syndrome, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review